WO2015068713A1 - AGENT DE TRAITEMENT DU CANCER DU CÔLON À L'AIDE DE miR-340 - Google Patents

AGENT DE TRAITEMENT DU CANCER DU CÔLON À L'AIDE DE miR-340 Download PDF

Info

Publication number
WO2015068713A1
WO2015068713A1 PCT/JP2014/079297 JP2014079297W WO2015068713A1 WO 2015068713 A1 WO2015068713 A1 WO 2015068713A1 JP 2014079297 W JP2014079297 W JP 2014079297W WO 2015068713 A1 WO2015068713 A1 WO 2015068713A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
colorectal cancer
carbonate apatite
cancer
particles
Prior art date
Application number
PCT/JP2014/079297
Other languages
English (en)
Japanese (ja)
Inventor
浩文 山本
祐一郎 土岐
森　正樹
秀始 石井
功士 三森
Original Assignee
国立大学法人大阪大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人大阪大学 filed Critical 国立大学法人大阪大学
Publication of WO2015068713A1 publication Critical patent/WO2015068713A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Definitions

  • the present invention relates to a therapeutic agent for colon cancer using miR-340. More specifically, the present invention relates to a therapeutic agent for colorectal cancer that can treat colorectal cancer and that can suppress cancer metastasis and the like to improve the prognosis. Furthermore, the present invention relates to a method for examining cancer metastasis to the liver in patients with intestinal cancer and a method for predicting prognosis of patients with colorectal cancer using miR-340 as a marker.
  • the presumed bone marrow-mediated metastasis mechanism includes the theory that cancer cells in the primary tumor home to the bone marrow and then become dormant to acquire drug resistance, or metastasize in the home bone marrow The theory of acquiring ability and transferring to other organs such as the liver is considered.
  • the detailed mechanism of cancer metastasis changes in the properties of cancer cells in the bone marrow, changes in the properties of host bone marrow cells themselves in a tumor-bearing state, etc.
  • colorectal cancer was once seen in many countries in Europe and the United States, but with the shift to Western lifestyles in Japan, it has become the third most common cancer disease among cancer patients in Japan. Yes.
  • colorectal cancer tends to cause cancer metastasis to the liver, lungs, etc., and metastasis that has become uncontrollable is a cause of death
  • colorectal cancer treatment has a prognosis such as suppression of metastasis. It is important to establish treatment strategies in
  • microRNA is a short RNA of about 22 bases that exists in the body, plays an important role in the control of gene expression, and is a therapeutic agent for various diseases caused by abnormal gene expression. It is expected to be used as a prognostic marker.
  • cancer treatment methods that supplement microRNAs whose expression is reduced in cancer-bearing states will administer microRNAs that were originally present in the body in non-cancer-bearing states, and it has been reported in animal experiments that there are few side effects. (For example, see Non-Patent Document 1), and application to humans is strongly expected.
  • microRNAs showing relevance to colorectal cancer For example, it has been reported that miR-340 can suppress the growth of colon cancer cells in vitro (see Non-patent Document 2), can be used as a diagnostic marker for colon cancer (see Patent Document 1), and the like. Thus, it has been reported that a plurality of microRNAs including miR-340 are related to colorectal cancer. However, the gene expression of bone marrow free cancer cells in colorectal cancer patients and the relationship between the prognosis and gene expression of colorectal cancer patients have not been analyzed, and microRNAs that play an important role in the prognosis of colorectal cancer metastasis, etc. Has not been identified. Therefore, regarding microRNA candidates that are related to colorectal cancer, what type of microRNA can be selected to establish colorectal cancer treatment that can treat colorectal cancer and improve the prognosis such as suppression of metastasis It has not been revealed.
  • microRNA drug delivery system
  • microRNA is a short RNA molecule of about 22 bases, it is easily degraded in vivo by the action of RNase, etc. and does not have specific recognition ability for tumor cells, so microRNA is simply administered in vivo. Alone, the microRNA cannot be accumulated in tumor cells in vivo, and the action of the microRNA cannot be exhibited effectively. Therefore, the establishment of DDS technology that accumulates administered microRNA in tumor cells is indispensable for cancer treatment using microRNA.
  • the present inventors have reported that complex particles obtained by complexing a polynucleotide to be introduced into tumor cells with carbonate apatite are effective as DDS for specifically accumulating and introducing the polynucleotide into tumor cells. (Refer nonpatent literature 3). However, a technique for applying the DDS technique to the treatment of colorectal cancer has not been studied yet.
  • An object of the present invention is to establish a colorectal cancer treatment technique that can treat colorectal cancer using microRNA and that can suppress cancer metastasis and the like to improve the prognosis.
  • Another object of the present invention is to establish a method for examining cancer metastasis to the liver in patients with intestinal cancer and a method for predicting prognosis of patients with colorectal cancer.
  • the present inventor first made a comprehensive comparison of microRNA expression of free cancer cells in the bone marrow in patients with colorectal cancer liver metastases and patients with colorectal cancer non-liver metastases. It was found that expression was decreased in bone marrow free cancer cells of patients with cancer liver metastasis. That is, it was found that miR-340 expression reduction is likely to be involved in colon cancer metastasis. In addition, the present inventor confirmed the expression of miR-340 in the excised tissue from patients with colorectal cancer. The miR-340 low expression group had a poorer prognosis than the miR-340 high expression group. I found.
  • a colorectal cancer patient having a colorectal cancer cell in which miR-340 expression is reduced has a poor prognosis after surgical treatment of colorectal cancer. Based on these findings, it was found that miR-340 supplementation therapy is effective in suppressing metastasis of colorectal cancer and improving the prognosis after surgery for colorectal cancer.
  • the present inventor has found that by administering composite particles in which microRNA is supported on carbonate apatite and complexed, colon cancer cell proliferation can be suppressed in vivo, and an antitumor effect can be effectively exhibited. .
  • the present invention has been completed by further studies based on such knowledge.
  • Item 1 A therapeutic agent for colorectal cancer comprising, as an active ingredient, composite particles in which miR-340 is supported on carbonate apatite particles.
  • Item 2. The therapeutic agent for colorectal cancer according to Item 1, wherein the carbonate apatite particles have an average particle size of 50 nm or less.
  • Item 3. The therapeutic agent for colon cancer according to item 1 or 2, which is administered to a colon cancer patient in which free cancer cells in bone marrow are observed and miR-340 is lowly expressed in the bone marrow free cancer cells.
  • the therapeutic agent for colorectal cancer according to Item 1 or 2 which is administered to a colorectal cancer patient having colorectal cancer cells in which the expression level of miR-340 is decreased, after resection of the colorectal cancer.
  • Item 5 An agent for preventing cancer metastasis in colorectal cancer patients, comprising, as an active ingredient, composite particles in which miR-340 is supported on carbonate apatite particles.
  • An agent for improving prognosis in patients after resection of colorectal cancer comprising as active ingredient composite particles in which miR-340 is supported on carbonate apatite particles.
  • a method for examining cancer metastasis to the liver in colorectal cancer patients comprising detecting the expression level of miR-340 in free cancer cells in bone marrow of colorectal cancer patients.
  • Item 8. A method for predicting the prognosis of a colorectal cancer patient, comprising detecting the expression level of miR-340 in colorectal cancer cells of the colorectal cancer patient.
  • Item 9. Use of composite particles in which miR-340 is supported on carbonate apatite particles for the production of a therapeutic agent for colorectal cancer.
  • a method for treating colorectal cancer comprising administering a therapeutically effective amount of composite particles in which miR-340 is supported on carbonate apatite particles to a colorectal cancer patient.
  • Item 12. Use of composite particles in which miR-340 is supported on carbonate apatite particles for the production of a preventive agent for cancer metastasis in colorectal cancer patients.
  • Item 13. A composite particle in which miR-340 is supported on carbonate apatite particles, used for preventing cancer metastasis in colorectal cancer patients.
  • a method for preventing cancer metastasis in colorectal cancer patients comprising administering a therapeutically effective amount of composite particles in which miR-340 is supported on carbonate apatite particles to colorectal cancer patients that are required to prevent cancer metastasis.
  • Item 15. Use of composite particles in which miR-340 is supported on carbonate apatite particles for the production of a prognostic improver in patients after resection of colorectal cancer.
  • a method for improving prognosis in a patient after resection of colorectal cancer wherein a therapeutically effective amount of the composite particles in which miR-340 is supported on carbonate apatite particles is administered to the patient after resection of colorectal cancer.
  • the therapeutic agent for colorectal cancer of the present invention by using miR-340, metastasis of colorectal cancer can be suppressed while suppressing the proliferation of colorectal cancer cells, so that colorectal cancer with a good prognosis is treated. It becomes possible. Furthermore, the therapeutic agent for colorectal cancer of the present invention uses miR-340 complexed with carbonate apatite to allow miR-340 administered in vivo to accumulate in colorectal cancer cells, thereby causing the intracellular Therefore, it is equipped with DDS technology required for practical use of colorectal cancer treatment, and is extremely useful in clinical practice.
  • cancer metastasis to the liver has occurred in the colon cancer patient or to the liver. Therefore, it is possible to presume colorectal cancer patients who have a high risk of cancer metastasis to the liver, and to perform appropriate treatment.
  • the method for predicting prognosis of colorectal cancer patients of the present invention determines whether or not prognosis is likely to deteriorate after surgical operation of colorectal cancer by using the expression level of miR-340 in colorectal cancer cells as an index. Since it can be estimated, it becomes possible to perform appropriate treatment at an early stage for postoperative colorectal cancer patients who have a high risk of prognosis deterioration.
  • Test Example 1 it is a diagram showing a cell sorting flow in which CD14 ⁇ CD45 ⁇ EpCAM + cells (BM4) were obtained from whole bone marrow cells (BM1).
  • BM4 CD14 ⁇ CD45 ⁇ EpCAM + cells
  • FIG. 2 shows the expression level of each mRNA level in CD14 ⁇ CD45 ⁇ EpCAM + cells (BM4) as a relative expression ratio with respect to the expression level of each mRNA level in BM2 (monocyte (hairball) cell). .
  • Experimental example 1 it is a figure which shows the result of having performed immunostaining of EpCAM, DAPI, and cytokeratin about CD14 - CD45 - EpCAM + cell (BM4).
  • Test Example 2 conditions in which colon cancer cell lines HCT116 and SW480 in In vitro were treated with pre-miR-340 (indicated as “pre-miR-340” in the figure), Pre-miR negative
  • Pre-miR negative control in the figure
  • Parent untreated conditions
  • Example 3 it is a figure which shows the result of having compared the expression level of miR-340 in a colon cancer cell and a normal mucosa cell.
  • the expression level of miR-340 is shown as a relative expression ratio with respect to the expression level of RNU6B.
  • Experimental example 4 it is a figure which shows the result of having divided into a miR-340 high expression group and a miR-340 low expression group, and putting together a 5-year disease-free survival rate and a 5-year total survival rate.
  • test Example 5 conditions treated with a preparation containing composite particles of pre-miR-340 and carbonate apatite particles (indicated as “pre-miR-340” in the figure), pre-miR negative control and carbonate apatite particles are included.
  • Pre-miR negative control in the figure
  • Parent untreated conditions
  • the therapeutic agent for colorectal cancer of the present invention is characterized by comprising composite particles in which miR-340 is supported on carbonate apatite particles as an active ingredient.
  • the therapeutic agent for colorectal cancer of the present invention will be described in detail.
  • miR-340 used in the present invention may be a mature miRNA (mature-miRNA), a hairpin type precursor miRNA (pri-miRNA), or a pre-miRNA in which a part of the pri-miRNA is cleaved. miRNA may be sufficient.
  • the pri-miRNA and pre-miRNA are processed in the colon cancer cells to become mature miRNA.
  • miR-340 used in the present invention may form a double-stranded precursor consisting of RNA having a complementary base sequence. The double-stranded precursor breaks the double strand in colon cancer cells and releases mature miRNA.
  • human-derived miR-340 when used for the treatment of human colorectal cancer, human-derived miR-340 may be used.
  • Specific examples of human-derived miR-340 used in the present invention include mature has-miR-340 shown below. Mature has-miR-340 (sense); 5'-UUAUAAAGCAAUGAGACUGAUU-3 (SEQ ID NO: 1) Mature has-miR-340 (antisense); 5'- AAUCAGUCUCAUUGCUUUAUAA-3 '(SEQ ID NO: 2)
  • Carbonate apatite particles Carbonate apatite has a structure in which hydroxyl group of hydroxyapatite (Ca 10 (PO 4 ) 6 (OH) 2 ) is partially substituted with CO 3 , and has a general formula Ca 10-m X m (PO 4 ) 6 (CO 3 ) 1-n Y n
  • X is an element that can partially replace Ca in carbonate apatite, and examples thereof include Sr, Mn, and rare earth elements.
  • m is a positive number of usually 0 or more and 1 or less, preferably 0 or more and 0.1 or less, more preferably 0 or more and 0.01 or less, and still more preferably 0 or more and 0.001 or less.
  • Y is a group or element that can partially substitute CO 3 in carbonate apatite, and examples thereof include OH, F, and Cl.
  • n is usually a positive number from 0 to 0.1, preferably from 0 to 0.01, more preferably from 0 to 0.001, and even more preferably from 0 to 0.0001.
  • the average particle size of the carbonate apatite particles used in the present invention is not particularly limited as long as it is a size that can be administered into a living body and transferred into colon cancer cells. From the viewpoint of efficient accumulation and migration into colorectal cancer cells, it is usually 50 nm or less, preferably 1 to 40 nm, more preferably 1 to 20 nm, more preferably 5 to 10 nm.
  • the average particle diameter of the carbonate apatite is a value measured by observing with a scanning probe microscope.
  • a scanning probe microscope confirm the measurement site with a CCD camera, and if there are huge particles (for example, a particle size of 5 ⁇ m or more) that are clearly unsuitable for measurement using a scanning probe microscope, They are removed from the measurement range.
  • the particle size means the particle size of an independent particle that can be recognized as a separate particle when measured with a scanning probe microscope. Therefore, when a plurality of particles are aggregated, the aggregate is determined as one particle.
  • Carbonate apatite particles can be obtained according to a known method. For example, it can be obtained by preparing it in the presence of calcium ions, phosphate ions and bicarbonate ions in an aqueous solution.
  • concentration of each ion in the aqueous solution is not particularly limited as long as the carbonate apatite particles are formed, and can be appropriately set with reference to the following.
  • the calcium ion concentration in the aqueous solution is usually 0.1 to 1000 mM, preferably 0.5 to 100 mM, more preferably 1 to 10 mM.
  • the phosphate ion concentration in the aqueous solution is usually 0.1 to 1000 mM, preferably 0.5 to 100 mM, and more preferably 1 to 10 mM.
  • the concentration of hydrogen carbonate ions in the aqueous solution is usually 1.0 to 10,000 mM, preferably 5 to 1000 mM, and more preferably 10 to 100 mM.
  • the supply source of calcium ions, phosphate ions and hydrogen carbonate ions is not particularly limited as long as these ions can be supplied in an aqueous solution, and examples thereof include water-soluble salts of these ions.
  • CaCl 2 can be used as the calcium ion source
  • NaH 2 PO 4 .2H 2 O can be used as the phosphate ion source
  • NaHCO 3 can be used as the carbonate ion source.
  • the aqueous solution for preparing the carbonate apatite particles may contain components other than the above-described ion supply sources and other substances as long as the carbonate apatite particles are formed.
  • Ca or CO 3 in the carbonate apatite may be partially substituted by adding fluorine ions, chlorine ions, Sr, Mn, or the like to the composition in the aqueous solution.
  • the addition amount of fluorine ions, chlorine ions, Sr, and Mn is preferably in a range that does not significantly affect the pH solubility and particle size range of the composite particles to be formed.
  • the aqueous solution for preparing the carbonate apatite particles may use water as a base, but various culture media and buffers for cell culture may be used.
  • the mixing order of each ion source and other substances in the aqueous solution is not particularly limited, and the aqueous solution may be mixed in any order as long as the target carbonate apatite particles are obtained. May be prepared. For example, a first solution containing calcium ions and other substances is prepared, and a second solution containing phosphate ions and hydrogen carbonate ions is separately prepared, and the first solution and the second solution Can be mixed to prepare an aqueous solution.
  • Carbonate apatite particles can be obtained by adjusting the pH of the aqueous solution containing each of the above ions to a range of 6.0 to 9.0 and leaving (incubating) for a certain period of time.
  • the pH of the aqueous solution in forming the carbonate apatite particles is, for example, 7.0 to 8.5, preferably 7.1 to 8.5, more preferably 7.2 to 8.5, still more preferably 7.3 to 8.5, particularly preferably 7.4 to 8.5, Most preferred is 7.5 to 8.0.
  • the temperature condition of the aqueous solution in forming the carbonate apatite particles is not particularly limited as long as the carbonate apatite particles are formed, but is usually 10 ° C or higher, preferably 25 to 80 ° C, more preferably 37 to 70 ° C or higher. Is mentioned.
  • the incubation time of the aqueous solution for forming the carbonate apatite particles is not particularly limited as long as the carbonate apatite particles are formed, but is usually 1 minute to 24 hours, preferably 10 minutes to 1 hour. The presence or absence of particle formation can be confirmed by observing under a microscope, for example.
  • the method for controlling the average particle size of the carbonate apatite particles to 50 nm or less is not particularly limited, and examples thereof include a method of ultrasonically treating the carbonate apatite particles formed in the aqueous solution.
  • the ultrasonic vibration treatment is not a treatment in which an ultrasonic vibrator such as an ultrasonic crusher or a homogenizer used for so-called microbial cell crushing is directly brought into contact with a sample, but generally a precision instrument or a test. This is a process using an ultrasonic cleaner in which an ultrasonic vibrator and a cleaning tank used for cleaning tubes and the like are integrated.
  • a liquid for example, water
  • float a container for example, a plastic tube
  • carbonate apatite particles on it
  • pass the liquid through the procedure to clean precision equipment a treatment in which ultrasonic waves are applied to an aqueous solution containing carbonate apatite particles.
  • the particle size of the carbonate apatite particles can be reduced to 50 nm or less simply and efficiently.
  • An apparatus that can be used for ultrasonic vibration treatment is capable of applying ultrasonic vibration to a container containing carbonate apatite particles indirectly through a solvent such as water, like the ultrasonic cleaner. If there is no particular limitation. From the viewpoint of versatility and ease of handling, it is preferable to use an ultrasonic cleaner equipped with an ultrasonic vibrator and a thermostatic bath.
  • the conditions for the above ultrasonic vibration treatment are not particularly limited as long as the particle diameter can be controlled within a predetermined range.
  • the temperature of the water tank can be appropriately selected from temperatures of 5 to 45 ° C., preferably 10 to 35 ° C., more preferably 20 to 30 ° C.
  • the high frequency output of the ultrasonic vibration treatment can be appropriately set, for example, in the range of 10 to 500 W, preferably 20 to 400 W, more preferably 30 to 300 W, and more preferably 40 to 100 W.
  • the oscillation frequency is usually 10 to 60 Hz, preferably 20 to 50 Hz, and more preferably 30 to 40 Hz.
  • the ultrasonic vibration treatment time is, for example, 30 seconds to 30 minutes, preferably 1 to 20 minutes, and more preferably 3 to 10 minutes.
  • the type of container containing carbonate apatite particles used when performing ultrasonic vibration treatment is not limited as long as the particles can be refined to a predetermined particle diameter range, depending on the volume of the aqueous solution and the purpose of use. Can be selected as appropriate. For example, a plastic tube having a capacity of 1 to 1000 ml can be used.
  • the ultrasonic vibration treatment is preferably performed in the presence of albumin (that is, a state in which albumin is added to an aqueous solution containing carbonate apatite particles).
  • albumin that is, a state in which albumin is added to an aqueous solution containing carbonate apatite particles.
  • the concentration of albumin in the aqueous solution containing carbonate apatite particles is not particularly limited as long as the effect of refining and / or suppressing reaggregation is obtained. For example, 0.1 to 500 mg / ml, preferably 1 to 100 mg / ml, More preferably, about 1 to 10 mg / ml can be added.
  • Composite particles of miR-340 and carbonate apatite particles The therapeutic agent for colorectal cancer of the present invention uses composite particles in which the miR-340 is supported by carbonate apatite particles and combined. By combining miR-340 with carbonate apatite particles in this way, miR-340 is efficiently accumulated in colon cancer cells in vivo by the action of carbonate apatite, and miR-340 is introduced into colon cancer cells. It becomes possible to make it. Moreover, since miR-340 can be released from the carbonate apatite particles in the cell after being introduced into the cell, it is possible to cause the miR-340 to exhibit a desired activity.
  • the composite particle in which miR-340 is supported on carbonate apatite particles refers to a state in which miR-340 is adsorbed and supported on carbonate apatite particles by ionic bonds, hydrogen bonds, and the like.
  • the method for forming the composite particles of miR-340 and carbonate apatite particles is not particularly limited.
  • a method of forming miR-340 and carbonate apatite particles by coexisting in an aqueous solution; in an aqueous solution for preparing carbonate apatite particles there may be mentioned a method in which miR-340 coexists with calcium ions, phosphate ions and hydrogen carbonate ions to simultaneously form carbonate apatite particles and combine miR-340 and carbonate apatite particles.
  • miR-340 and carbonate apatite particles are combined, the formation of carbonate apatite particles and the combination of miR-340 and carbonate apatite particles simultaneously, miR-340 is added to the aqueous solution used for the preparation of carbonate apatite.
  • aqueous solution used for the preparation of carbonate apatite.
  • 0.1 to 1000 nM preferably 0.5 to 500 nM, more preferably 1 to 200 nM may be added.
  • the ratio of miR-340 and carbonate apatite particles is not particularly limited, and may be appropriately set according to the dose of miR-340. For example, when 2 mg of miR-340 is combined with carbonate apatite particles, 5 mg of miR-340 is added to 1 L of an aqueous solution for preparing the carbonate apatite particles described above to form carbonate apatite particles and miR-340. And carbonate apatite particles may be combined at the same time.
  • the composite particles of miR-340 and carbonate apatite particles may carry other drugs such as anticancer agents as long as the effects of the present invention are not impaired.
  • anticancer agents include, but are not limited to, alkylating agents such as cyclophosphamide hydrate, ifosfamide, thiotepa, busulphalan, melphalan, nimustine hydrochloride, ranimustine, dacarpazine, temozolomide; methotrexate, pemetrexed sodium Antimetabolites such as hydrate, fluorouracil, doxyfluridine, capecitabine, tagafur, cytarabine, gemcitabine hydrochloride, fludarabine phosphate, nelarabine, cladribine, levofolinate calcium; doxorubicin hydrochloride, daunorubicin hydrochloride, prrubicin hydrochloride, epirubicin hydrochloride isal Salt,
  • the therapeutic agent for colorectal cancer of the present invention is used in a state where composite particles of miR-340 and carbonate apatite particles are dispersed in a solvent suitable for administration to a living body.
  • carbonate apatite particles can be obtained by dissolving various ion supply substances in a solvent such as water, a medium, or a buffer. From the viewpoint of osmotic pressure, buffer capacity, sterility, etc., it is not necessarily suitable for administration to a living body (intravascular administration).
  • the carbonate apatite particles are usually separated from the solvent by centrifugation and collected.
  • An operation to replace the solvent is necessary.
  • the carbonate apatite particles are aggregated and the particles become enormous, so that the state changes to a state unsuitable for administration to a living body. Therefore, by adding the agglomerated carbonate apatite particles to a solvent suitable for administration to the living body and then performing the ultrasonic vibration treatment described above, the composite particles of miR-340 and carbonate apatite particles can be used for administration to the living body. It can be dispersed in a suitable solvent with an appropriate particle size (preferably an average particle size of 50 nm or less).
  • the therapeutic agent for colorectal cancer of the present invention is applied to colon cancer patients for the purpose of treating colorectal cancer.
  • the therapeutic agent for colorectal cancer of the present invention may be used as a preventive agent for cancer metastasis (particularly, a metastasis preventive agent for liver) in colorectal cancer patients.
  • the therapeutic agent for colorectal cancer of the present invention may be administered for the purpose of preventing recurrence or metastasis after removing colorectal cancer from a colorectal cancer patient, or an agent for improving prognosis in a patient after resection of colorectal cancer or It can also be used as a cancer metastasis preventive agent (particularly a metastasis preventive agent to the liver).
  • a colon cancer patient in which free bone marrow cancer cells are observed by the present inventor and miR-340 is lowly expressed in the bone marrow free cancer cells is It has been elucidated that cancer metastasis is likely to occur. Therefore, the therapeutic agent for colorectal cancer of the present invention is administered to a colon cancer patient in which free cancer cells in bone marrow are observed and miR-340 is lowly expressed in the bone marrow free cancer cells. -340 replacement therapy can effectively treat colorectal cancer patients and suppress the transfer to the liver.
  • miR-340 is lowly expressed in bone marrow free cancer cells is determined by miR-340 in bone marrow free cancer cells obtained from patients with non-metastatic colorectal cancer (hereinafter referred to as “free cancer in liver non-metastatic bone marrow”).
  • the expression level of miR-340 is sometimes measured in advance, and the amount of miR-340 in bone marrow free cancer cells obtained from colorectal cancer patients and the amount of free cancer cells miR in liver non-metastatic bone marrow -340 by comparing quantities.
  • the amount of miR-340 in bone marrow free cancer cells obtained from a colorectal cancer patient is lower than that of liver non-metastatic bone marrow free cancer cells miR-340, in particular, about 1/2 or less, about 1/4 or less, Alternatively, when the ratio is about 1 / 7.5 or less, it is estimated that the colorectal cancer patient has metastasized to the liver or is likely to occur, and administration of the therapeutic agent for colorectal cancer of the present invention is performed. MiR-340 replacement therapy is effective.
  • Measurement of the amount of miR-340 in bone marrow free cancer cells can be performed according to a conventionally known method. For example, free cancer cells in bone marrow are separated from bone marrow of colon cancer patients according to a known technique, and RNA samples are obtained from the free cancer cells in bone marrow by the guanidine-cesium chloride ultracentrifugation method, acidic guanidine-phenol-chloroform (AGPC) method, etc. And measure the amount of miR-340.
  • the method for measuring the amount of miR-340 is not particularly limited, and examples thereof include a microarray method, an RT-PCR method, a real-time RT-PCR method, and a northern blot method.
  • the present inventor tends to deteriorate the prognosis of colorectal cancer patients having colorectal cancer cells in which the expression level of miR-340 is reduced after the colon cancer is excised. It has been elucidated. Therefore, the therapeutic agent for colorectal cancer of the present invention is supplemented with miR-340 by administering it after colorectal cancer resection to colorectal cancer patients having colorectal cancer cells in which the expression level of miR-340 is decreased. The therapy can also effectively suppress the prognosis.
  • miR-good prognosis group miR the average expression level of miR-340 in colorectal cancer cells derived from colorectal cancer patients with good prognosis.
  • -340 dose average value ”) in advance, and miR-340 amount in colon cancer cells of colon cancer tissue removed from colorectal cancer patients and average value of colon cancer cell miR-340 amount This is done by comparing When the amount of miR-340 in colon cancer cells obtained from a colorectal cancer patient is lower than the average value of miR-340 amount in the good prognosis group, in particular, about 1 / 1.2 or less, about 1/2 or less, or 1 When the ratio is about / 3 or less, it is presumed that the prognosis after surgery is likely to deteriorate in the colon cancer patient, and miR-340 supplementation therapy by administration of the therapeutic agent for colorectal cancer of the present invention is effective.
  • the amount of miR-340 in colorectal cancer cells can be measured according to a conventionally known method.
  • colon cancer cells are separated from the excised colon cancer tissue according to a known method, and RNA samples are prepared from the colon cancer cells in the same manner as in the case of free cancer cells in the bone marrow, and the amount of miR-340 is measured. Just do it.
  • the method for administering the therapeutic agent for colorectal cancer of the present invention is not particularly limited as long as the therapeutic agent for colorectal cancer of the present invention can be delivered to colorectal cancer in vivo.
  • it is intravascular (intraarterial or intravenous).
  • injection, continuous infusion, subcutaneous administration, local administration, intramuscular administration and the like can be mentioned.
  • intraarterial and intravenous administration is preferable.
  • the dose of the colorectal cancer therapeutic agent of the present invention is appropriately set according to the patient's symptom level, the patient's gender, age, etc., and thus cannot be uniformly defined.
  • the weight of miR-340 In conversion about 15 to 70 mg / m 2 (body surface area) per day can be mentioned.
  • the therapeutic agent for colorectal cancer of the present invention can be administered after the composite particles of miR-340 and carbonate apatite particles are dispersed in the form of fine particles by ultrasonic vibration treatment, and then the particles aggregate. It is desirable to do this promptly. For example, administration within 1 minute, preferably within 30 seconds after the ultrasonic vibration treatment is suitable. However, as described above, in the case where the aggregation of carbonate apatite particles is suppressed by adding albumin, administration can be performed several minutes to several tens of minutes after the ultrasonic vibration treatment.
  • the present invention further provides a method for examining cancer metastasis to the liver in colorectal cancer patients, wherein the expression level of miR-340 in free bone marrow cancer cells of colorectal cancer patients is detected. If the expression level of miR-340 is decreased in the test method, it is predicted that cancer metastasis to the liver has occurred or that the risk of cancer metastasis to the liver is high.
  • Whether the expression level of miR-340 in bone marrow free cancer cells is reduced or not is determined by miR-340 in bone marrow free cancer cells obtained from patients with non-metastatic colorectal cancer (hereinafter referred to as “liver non-metastatic bone marrow free”).
  • the expression level of "cancerous miR-340" may be measured in advance, and the amount of miR-340 in bone marrow free cancer cells obtained from patients with colorectal cancer and the amount of free cancer cells in non-metastatic bone marrow This is done by comparing the amount of miR-340.
  • the amount of miR-340 in bone marrow free cancer cells obtained from a colorectal cancer patient is lower than that of liver non-metastatic bone marrow free cancer cells miR-340, in particular, about 1/2 or less, about 1/4 or less, Alternatively, when the ratio is about 1 / 7.5 or less, the colorectal cancer patient is predicted to have cancer metastasis to the liver or have a high risk of cancer metastasis to the liver.
  • the method for measuring the amount of miR-340 in bone marrow free cancer cells is as described in the column “Therapeutic agent for colorectal cancer”.
  • the present invention further provides a prognosis prediction method for colorectal cancer patients, characterized by detecting the expression level of miR-340 in colorectal cancer cells of colorectal cancer patients. If the expression level of miR-340 is decreased in the prediction method, the risk of recurrence and metastasis after surgery is high, and the prognosis is predicted to be easily deteriorated.
  • Whether or not the expression level of miR-340 in colorectal cancer cells is reduced is determined in advance by measuring the mean value of miR-340 in the good prognosis group, in colorectal cancer cells of colorectal cancer tissue removed from colorectal cancer patients This is performed by comparing the amount of miR-340 and the average value of colorectal cancer cell miR-340.
  • the amount of miR-340 in colorectal cancer cells obtained from a colorectal cancer patient is lower than the mean value of miR-340 amount in the good prognosis group, particularly about 1 / 1.2 or less, about 1/2 or less, or 1 / When it is about 3 or less, it is presumed that the colorectal cancer patient has a high risk of postoperative recurrence and metastasis, and prognosis is likely to deteriorate.
  • the method for measuring the amount of miR-340 in colorectal cancer cells and normal colorectal mucosa cells is as described in the column of “Therapeutic agent for colorectal cancer”.
  • Test Example 1 Comprehensive examination of microRNA expression in free bone marrow cancer cells derived from colon cancer patients Recovery of free cancer cells in bone marrow derived from colorectal cancer patients Free cancer cells in bone marrow were isolated from 7 patients with colorectal liver metastases and 12 patients with colorectal cancer non-liver metastases by the following method. Anesthesia is administered before surgery for colorectal cancer patients, and 20 mL of bone marrow fluid (total volume of 40 mL) is collected from the left and right iliac crests, and mononuclear cells (total bone marrow cells, BM1) by standard Ficoll-Hypaque gradient method was recovered.
  • MACS TM pro using anti-CD14 immunobeads (Milteny Biotec) (Milteny Biotec, Bergisch Gladbach, Germany) performed magnetic bead cell sorting to remove CD14 + cells (BM2) from BM1 and collect CD14 ⁇ cells.
  • MACS TM pro using anti-CD14 immunobeads (Milteny Biotec) (Milteny Biotec, Bergisch Gladbach, Germany) performed magnetic bead cell sorting to remove CD14 + cells (BM2) from BM1 and collect CD14 ⁇ cells.
  • the magnetic bead cell sorting using anti-CD45 immunobead (Milteny Biotec)
  • CD14 - CD45 + cells were removed (BM3)
  • CD14 - - CD14 from cells CD45 - cells were harvested.
  • FIG. 1 shows a cell sorting flow for obtaining CD14 ⁇ CD45 ⁇ EpCAM + cells (BM4) from whole bone marrow cells (BM1).
  • BM4 CD14 ⁇ CD45 ⁇ EpCAM + cells
  • BM4 the amount of mRNA of CEA, which is a tumor marker, and the amount of mRNA of MYC, which is an oncogene, are 19.5 times and 2.26 times that of BM2 (monocyte (hairball) cells), respectively. It was. The result of the gene expression of BM4 is consistent with the gene expression of cancer cells, and it was confirmed that the cancer cells were recovered as BM4. Furthermore, BM4 was immunostained using antibodies against EpCAM, DAPI, and cytokeratin. The results are shown in FIG. From the result of this immunostaining, it was confirmed that cancer cells were recovered as BM4.
  • RNA array (Agilent Microarray Kit; G4470C) with 886 microRNAs (version 12.0 of the Sanger miRNA database; http://www.mirbase.org/) .
  • the signal intensity of each hybridization was measured using Extraction Software Version A.7.5.1 (Agilent Technologies). P value was calculated using paired t-test.
  • microRNAs shown in Table 1 were detected as microRNAs that differed in expression level by 1.5 times or more between patients with colorectal cancer liver metastases and patients with colorectal cancer non-liver metastases.
  • Table 1 the expression level of miR-340 in the free bone marrow cancer cells derived from patients with colorectal cancer liver metastases was significantly lower than that in patients with colorectal cancer non-liver metastases. From this result, it became clear that colon cancer patients whose miR-340 expression level is low in bone marrow free cancer cells are likely or likely to undergo cancer metastasis to the liver. It is also clear that miR-340 replacement therapy is effective for patients with colorectal cancer whose miR-340 expression level is low in bone marrow free cancer cells to suppress cancer metastasis to the liver. became.
  • Test Example 2 Inhibition effect of miR-340 on colon cancer cell line in vitro The following tests were performed using HCT116 strain and SW480 strain (both purchased from ATCC) as human colon cancer cells.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • antibiotic solution Sigma, St. Louis, MO
  • Pre-miR negative control (Applied Biosystems; sense 5'-UAAAUGUACUGCGCGUGGAGAGGAA-3 '(sequence number 3), antisense 5'-UUCCUCUCCACGCGCAGUACAUUUA-3' (sequence number 4) was used as a control.
  • Transfected colon cancer cells were seeded in a 2-well dish at 3-4 ⁇ 10 4 cells / well and cultured for 72 hours. After the culture, the number of cells was measured using NucleoCounter kit (Chemometec, Gydevang 43, DK-3450 Alleroed, Denmark).
  • Test Example 3 Comparison of miR-340 expression in colorectal cancer cells and normal mucosal cells miR-340 expression levels of colorectal cancer cells and normal mucosal cells (derived from normal colorectal mucosa and submucosa of colorectal cancer patients) were compared with those in Test Example 1 above. It measured by the same method.
  • Test Example 4 Correlation between miR-340 expression level in colorectal cancer cells and clinicopathological findings and prognosis Colorectal cancer patients who received surgical treatment at Osaka University Hospital and two related hospitals between 1999 and 2010 136 samples of primary colon cancer cells were collected. Each sample was stored at ⁇ 80 ° C. with RNAlater TM until RNA extraction was performed. Of the 136 colon cancer patients, stage 0 was 4 cases, stage I was 15 cases, stage II was 38 cases, stage IIIA / B was 52 cases, and stage IIIC was 27 cases.
  • Table 2 shows the results of a summary of the clinicopathological findings divided between the miR-340 low expression group and the miR-340 high expression group. The results were divided into the miR-340 low expression group and the miR-340 high expression group for 5 years.
  • FIG. 6 shows a summary of disease-free survival rate (5-years Disease Free Survival) and 5-year overall survival rate (5-years Overall Survival).
  • the miR-340 low expression group was larger than the miR-340 high expression group (P) ⁇ 0.001), but other factors showed low miR-340 expression. There was no difference between the group and miR-340 high expression group.
  • both the 5-year disease-free survival rate and the 5-year total survival rate were lower in the miR-340 low expression group than in the miR-340 high expression group. That is, it was revealed that colon cancer patients having colon cancer cells in which miR-340 is lowly expressed have a high risk of recurrence and metastasis after surgery and tend to have a poor prognosis. In addition, it was also clarified from this result that prognosis worsening can be suppressed by colorectal cancer patients having colorectal cancer cells in which miR-340 is lowly expressed by miR-340 supplementation therapy.
  • Test Example 5 Treatment effect of colon cancer with miR-340 and carbonate apatite particles in vivo HCT116 per 100 ⁇ L of medium / Matrigel solution containing Matrigel (BD Biosciences, San Jose, Calif.) And medium at a volume ratio of 1: 1
  • the cells were mixed to 1 ⁇ 10 6 cells, and 100 ⁇ L of the cells were injected subcutaneously into the lower part of the back on the left and right sides of female nude mice (NIHON CLEA, Tokyo, Japan).
  • NIHON CLEA female nude mice
  • the tail vein was injected so that the particles were 30 ⁇ g.
  • the administration of the formulation was repeated once a day for 3 days.
  • a test was similarly performed using a preparation containing composite particles prepared using Pre-miR negative control (SEQ ID NO: 3 and SEQ ID NO: 4) instead of Pre-miR-340.
  • the solution is centrifuged at 15000 rpm ⁇ 5 minutes, and the resulting pellet is dispersed in physiological saline to obtain a dispersion of composite particles in which miR340 is encapsulated in carbonate apatite particles.
  • This is subjected to ultrasonic vibration treatment for 10 minutes.
  • a preparation containing a complex composed of carbonate apatite nanoparticles including miR340 was obtained.
  • the dispersion liquid contained in a plastic container is floated on water set at 20 ° C. using a water bath having an ultrasonic vibration function, and the high frequency output is 55 W and the oscillation frequency is 38 kHz. Went for a minute.
  • the formulation thus obtained was immediately used for the test. In addition, it has been confirmed in the measurement using a scanning probe microscope that the thus obtained preparation has an average particle diameter of 50 nm or less of a complex composed of carbonate apatite nanoparticles including miR340.
  • the tumor size (major axis x minor axis x minor axis x 1/2) of the back of the mouse was measured over time.
  • the obtained results are shown in FIG.
  • FIG. 7 when the composite particles of miR-340 and carbonate apatite particles were administered via the tail vein, tumor growth was significantly suppressed compared to the control (P ⁇ 0.05). From this result, when miR-340 and carbonate apatite composite particles are administered intravenously, miR-340 is efficiently delivered to colon cancer cells and transferred to colon cancer cells. It was revealed that the anti-tumor action by -340 can be exerted effectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'objectif de la présente invention est d'établir une technologie de traitement du cancer du côlon qui peut traiter le cancer du côlon à l'aide de microARN et qui peut entraîner un pronostic favorable par la suppression des métastases et analogues. Au moyen de l'administration de particules composites combinées par le support de microARN sur du carbonate-apatite, il est possible de supprimer la prolifération de cellules du cancer du côlon in vivo et il est possible de faire preuve d'un effet antitumoral efficace.
PCT/JP2014/079297 2013-11-05 2014-11-05 AGENT DE TRAITEMENT DU CANCER DU CÔLON À L'AIDE DE miR-340 WO2015068713A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-229482 2013-11-05
JP2013229482A JP2015089874A (ja) 2013-11-05 2013-11-05 ｍｉＲ−３４０を用いた大腸癌の治療剤

Publications (1)

Publication Number Publication Date
WO2015068713A1 true WO2015068713A1 (fr) 2015-05-14

Family

ID=53041490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/079297 WO2015068713A1 (fr) 2013-11-05 2014-11-05 AGENT DE TRAITEMENT DU CANCER DU CÔLON À L'AIDE DE miR-340

Country Status (2)

Country Link
JP (1) JP2015089874A (fr)
WO (1) WO2015068713A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449155B2 (en) 2015-11-09 2019-10-22 Medical Corporation Ijunkai Drug introducing agent for administration into a living body and manufacturing method
WO2024172057A1 (fr) * 2023-02-15 2024-08-22 国立大学法人 東京医科歯科大学 Construction de miarn artificiel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113030A2 (fr) * 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Profils d'expression de micro-arn de cancer humain prédictifs de réponse à la chimiothérapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5145557B2 (ja) * 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
JP5781732B2 (ja) * 2010-01-13 2015-09-24 国立大学法人鳥取大学 がん抑制ｍｉＲＮＡ
WO2012063894A1 (fr) * 2010-11-12 2012-05-18 国立大学法人愛媛大学 Compositions contenant des oligonucléotides antisens par rapport à des micro-arn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113030A2 (fr) * 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Profils d'expression de micro-arn de cancer humain prédictifs de réponse à la chimiothérapie

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
SEIICHI TADA ET AL.: "Design of the biocompatible nanocarrier and efficient delivery of DNA, RNA or protein", REGENERATIVE MEDICINE, vol. 6, no. 2, May 2007 (2007-05-01), pages 180 - 191 *
SUN,Y. ET AL.: "miR-124,miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect", ONCOL. REP., vol. 28, no. 4, October 2012 (2012-10-01), pages 1346 - 1352 *
TAKEYAMA,H. ET AL.: "Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer", MOL. CANCER THER., vol. 13, no. 4, April 2014 (2014-04-01), pages 976 - 985 *
TOKARZ,P. ET AL.: "The role of microRNA in the metastatic colorectal cancer and its significance in cancer prognosis and treatment", ACTA BIOCHIM. POL., vol. 59, no. 4, 21 November 2012 (2012-11-21), pages 467 - 474, Retrieved from the Internet <URL:http://www.actabp.pl/pdf/4_2012/467.pdf> [retrieved on 20141125] *
ZOHRA,F.T. ET AL.: "Drastic effect of nanoparticles on liposome-mediated mRNA delivery to mammalian cells", ANAL. BIOCHEM., vol. 345, no. 1, pages 164 - 166 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449155B2 (en) 2015-11-09 2019-10-22 Medical Corporation Ijunkai Drug introducing agent for administration into a living body and manufacturing method
WO2024172057A1 (fr) * 2023-02-15 2024-08-22 国立大学法人 東京医科歯科大学 Construction de miarn artificiel

Also Published As

Publication number Publication date
JP2015089874A (ja) 2015-05-11

Similar Documents

Publication Publication Date Title
Mc Namee et al. Extracellular vesicles and anti-cancer drug resistance
US20040023925A1 (en) Method for enhancing the effectiveness of therapies of hyperproliferative diseases
US20040223971A1 (en) Composition and uses of galectin antagonists
D'Asti et al. Tissue factor regulation by miR-520g in primitive neuronal brain tumor cells: a possible link between oncomirs and the vascular tumor microenvironment
Sun et al. ADAM17-regulated CX3CL1 expression produced by bone marrow endothelial cells promotes spinal metastasis from hepatocellular carcinoma
Mirzaei et al. Exosome-mediated miR-200a delivery into TGF-β-treated AGS cells abolished epithelial-mesenchymal transition with normalization of ZEB1, vimentin and Snail1 expression
JP6543612B2 (ja) 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
JP7158035B2 (ja) ｍｉＲＮＡを使用した癌幹細胞の増殖抑制剤
EP1980257A1 (fr) Compositions et utilisations d&#39;antagonistes de galectine
WO2016166600A1 (fr) Administration de micro-arn à l&#39;aide de microparticules de cellules souches mésenchymateuses
WO2015068713A1 (fr) AGENT DE TRAITEMENT DU CANCER DU CÔLON À L&#39;AIDE DE miR-340
JP2015155392A (ja) グルコースと炭酸アパタイトを使用した抗癌剤
TW201625273A (zh) 細胞凋亡誘導劑
JP6560190B2 (ja) 抗腫瘍作用を有する新規ｒｎａ配列
JP5990274B2 (ja) 前立腺病態の処置のためのｅｎ２、ｐａｘ２、および／またはｄｅｆｂ１の標的化
WO2023055885A2 (fr) Inhibition de l&#39;ezh2 dans le cancer du pancréas
WO2023081299A1 (fr) Dérivation d&#39;une population d&#39;exosomes enrichie et purifiée provenant d&#39;individus atteints d&#39;une affection pulmonaire chronique progressive pour la détection non invasive, la stadification et le suivi médical de la progression de la maladie
WO2020246380A1 (fr) Agent thérapeutique contre le cancer
WO2017223492A1 (fr) Compositions, dispositifs, et procédés d&#39;administration d&#39;arnmicro
CN115461461A (zh) 用于促进免疫原性细胞死亡的miRNA-193a
Zhang et al. Research progress of extracellular vesicles in the treatment of ovarian diseases
Lanning The role of prostate cancer small extracellular vesicles on the bone environment
Nantais 1 Significance of Precision Medicine in Oncology
Ketteler Role of Caveolin-1 for modulating the radiation response in the context of tumor stroma interactions
Sakuragi et al. TGF-β type I receptor inhibitor suppresses polarization of tumor-associated macrophages to the M2 phenotype and exerts antitumor effects on colorectal cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14859365

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14859365

Country of ref document: EP

Kind code of ref document: A1